Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin Assisted Psychotherapy for Fear of Recurrence in Breast and Ovarian Cancer
NCT06430541Phase 1Recruiting
- Sponsor
- University of Colorado Denver
- Start
- Nov 2024
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of psilocybin in Fear of Cancer Recurrence (FCR), sponsored by University of Colorado Denver. Primary endpoint: Fear of Cancer Recurrence Inventory at 24 weeks. Started Nov 2024; status: recruiting.
02
Drugs
psilocybin
03
Conditions
Fear of Cancer Recurrence (FCR)
Beyond the preview
Go deeper on NCT06430541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06430541.